Instruction: "Lazolvan" (solution)

The drug "Lazolvan" is a mucolytic and expectorant drug. According to its physico-chemical properties, it is a colorless solution that does not have impurities. The preparation contains an active active ingredient, which is ambroxol hydrochloride, as well as auxiliary substances such as disodium hydrophosphate dihydrate, sodium chloride, citric acid and water for injection. Manufacturers of medicines also produce the drug "Lazolvan" in the form of tablets and syrup. Before starting the course of treatment with the use of medication, you should consult a specialist.

The main indications for use are the instructions. "Lazolvan" (solution) is recommended for various chronic and acute respiratory diseases, which are accompanied by the release of sputum viscous type:

- pneumonia;

- acute and chronic bronchitis;

- obstructive lung diseases of chronic type;

- bronchial asthma with a difficult process of sputum discharge;

- respiratory distress syndromes in premature infants;

- bronchoectatic diseases.

Pharmacological effects on the body also describes the instructions. "Lazolvan" (solution) increases the secretion of mucus in the respiratory tract. Ambroxol hydrochloride normalizes the synthesis of surfactant in the lungs and increases ciliary activity. These processes contribute to improving the excretion and removal of mucus from the body, as well as reducing cough.

The drug "Lazolvan" (solution), the instruction for its use recommends it for internal administration, is often used for inhalation. During this procedure, the aerosolized agent directly enters the bronchial mucosa and exerts its therapeutic effect. The drug "Lazolvan" (solution), introduced into the body through inhalation, promotes the expansion of the bronchi, which makes it possible to strengthen the expectorant effect of the medication.

The drug increases the amount of sputum by activating the cells of the mucosa responsible for its production, and also contributes to its liquefaction. Under the action of the drug cilia, located in the epithelium of the bronchi, begin to produce at a higher rate of translational movement, directed to the exit from the respiratory tract, freeing the body from sputum.

Once in the body in the process of inhalation, the drug is able to reach the most remote corners of the bronchi. Settling on the walls of the alveoli, which are a tissue of the lung, the drug prevents them from sticking together, stimulating the production of a special substance - surfactant.

The inhalation process describes the instructions in detail. "Lazolvan" (solution) is recommended for use in inhalations in combination with taking the drug inside. This course of therapy is effective in all bronchopulmonary diseases, which are inflammatory.

Contraindications prohibiting the use of the drug are: increased sensitivity to ambroxol or other substances that make up the product. Side effects indicate the instruction. "Lazolvan" (solution) can cause minor digestive system disorders, which can be expressed as heartburn. Also, when taking medication, dyspepsia may develop, and nausea, vomiting, and allergic reactions may occur.

The use of the drug during the course of treatment with antibiotics helps to increase the concentration of the latter in the lung tissue. Taking a medicine at the same time as antitussive medications can cause difficulty in withdrawing sputum from the body.